Liang-Shan Da

Case Report: Site-specific therapy guided by the 90-gene expression assay in cancer of unknown primary: lenvatinib plus camrelizumab for occult renal cell carcinoma

Cancer of unknown primary (CUP) is primarily treated with empirical chemotherapy, but clinical outcomes remain unsatisfactory. We present the case of a 62-year-old male with asymptomatic left supraclavicular lymphadenopathy. Fine-needle aspiration revealed metastatic poorly differentiated carcinoma. Comprehensive evalu...